Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTA101 UCAR-T in Relapsed/Refractory CD19+ B-line Hematological Malignancy
NCT04227015Phase 1Recruiting
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CTA101 in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Jan 2020; status: recruiting.
02
Drugs
CTA101
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04227015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227015.